Hong-An Troung

Title: Innovations of Hong-An Troung in Cancer Therapeutics

Introduction

Hong-An Troung is a notable inventor based in San Francisco, CA, who has made significant contributions to the field of cancer therapeutics. With a focus on innovative antibody development, Troung's work aims to enhance treatment options for patients battling cancer.

Latest Patents

Hong-An Troung holds a patent titled "Antibodies against TIM3 and uses thereof." This patent provides antibodies, or antigen-binding portions thereof, that specifically bind to the T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. The patent outlines various therapeutic applications of these antibodies, particularly in the treatment of cancer. Additionally, it includes details about cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising these polynucleotides.

Career Highlights

Currently, Hong-An Troung is associated with Bristol-Myers Squibb Company, where he continues to advance his research in immunotherapy. His work is pivotal in developing new strategies to combat cancer through innovative antibody therapies.

Collaborations

Throughout his career, Troung has collaborated with esteemed colleagues, including Xiao Min Schebye and Mark J Selby. These partnerships have fostered a collaborative environment that enhances the research and development of novel therapeutic solutions.

Conclusion

Hong-An Troung's contributions to the field of cancer therapeutics through his innovative patent on TIM3 antibodies exemplify the impact of dedicated research in improving treatment options for cancer patients. His work at Bristol-Myers Squibb Company continues to pave the way for advancements in immunotherapy.